The results of KM OS analysis demonstrated that EPHX2 was identified as a protective factor for patients with ACC, CESC, KIRC, LIHC, Mesothelioma (MESO), PAAD, and uveal melanoma (UVM), and as a risk factor for patients with LGG (Figure 3A). Here, EPHX2 is linked to pancreatic adenocarcinoma.